Mangoceuticals (NASDAQ:MGRX – Get Free Report) and Quipt Home Medical (NASDAQ:QIPT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, profitability, risk and dividends.
Valuation & Earnings
This table compares Mangoceuticals and Quipt Home Medical”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mangoceuticals | $730,000.00 | 14.77 | -$9.21 million | ($5.79) | -0.75 |
| Quipt Home Medical | $245.91 million | 0.45 | -$6.76 million | ($0.17) | -14.94 |
Quipt Home Medical has higher revenue and earnings than Mangoceuticals. Quipt Home Medical is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Insider & Institutional Ownership
56.7% of Mangoceuticals shares are owned by institutional investors. Comparatively, 42.9% of Quipt Home Medical shares are owned by institutional investors. 39.3% of Mangoceuticals shares are owned by insiders. Comparatively, 13.4% of Quipt Home Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Mangoceuticals and Quipt Home Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mangoceuticals | -1,237.00% | -138.00% | -118.88% |
| Quipt Home Medical | -2.90% | -6.70% | -2.94% |
Analyst Recommendations
This is a breakdown of current ratings for Mangoceuticals and Quipt Home Medical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mangoceuticals | 0 | 0 | 0 | 0 | 0.00 |
| Quipt Home Medical | 1 | 0 | 3 | 2 | 3.00 |
Quipt Home Medical has a consensus target price of $6.25, indicating a potential upside of 146.06%. Given Quipt Home Medical’s stronger consensus rating and higher possible upside, analysts plainly believe Quipt Home Medical is more favorable than Mangoceuticals.
Summary
Quipt Home Medical beats Mangoceuticals on 10 of the 15 factors compared between the two stocks.
About Mangoceuticals
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
About Quipt Home Medical
Quipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment. It offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep apnea, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. is headquartered in Wilder, Kentucky.
Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
